Prøve GULL - Gratis

Maharashtra, powerhouse of Indian pharma industry

Chronicle Pharmabiz

|

September 18, 2025

MAHARASHTRA, particularly the Mumbai-Pune corridor, is indisputably the powerhouse of the Indian pharmaceutical industry.

- Namdeo Shinde

Contributing approximately 25-30 per cent of India's total pharmaceutical output and housing over 40 per cent of the nation's pharmaceutical R&D centres, the state is a critical hub for manufacturing, innovation, and exports. However, this preeminent position is challenged by intense domestic competition, infrastructural bottlenecks, environmental concerns, and a rapidly evolving global regulatory landscape.

Region-wise distribution of pharma industry

The pharmaceutical industry in Maharashtra is strategically concentrated in key regional clusters, each with a distinct role. The Mumbai Metropolitan Region (MMR), encompassing Mumbai, Thane, Navi Mumbai, and Palghar, remains the historical and corporate heartland.

It hosts the headquarters of industry giants like Cipla, Sun Pharma, and multinational corporations such as Pfizer and GSK, serving as a central hub for corporate functions, regulatory affairs, marketing, and R&D. While still a dominant centre for formulating complex drugs and vaccines, its high operational costs and space constraints are gradually shifting manufacturing focus to other regions.

According to the Maharashtra Industrial Development Corporation (MIDC), the Mumbai and Konkan region continues to account for a significant, though dynamically changing, portion of the state's pharmaceutical units.

In contrast, Pune has solidified its status as the emerging "Pharma & Biotech Capital" of India. The region, including Pune city, Pimpri-Chinchwad, and Hinjawadi, is an epicentre of innovation, hosting a dense cluster of R&D centres, CRAMS players, and biotech startups, bolstered by world-class institutions like the National Chemical Laboratory and the Serum Institute of India. A report by the India Brand Equity Foundation (IBEF) highlights its prominence, noting over 800 manufacturing units in the broader region.

FLERE HISTORIER FRA Chronicle Pharmabiz

Chronicle Pharmabiz

Chronicle Pharmabiz

Home-grown CAR-T cell therapies gaining ground

INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.

time to read

4 mins

November 27, 2025

Chronicle Pharmabiz

NPPA extends price fixation on orthopaedic implants for 1 year

IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

FICCI envisages it's Smart AAMs to boost healthcare

In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

DoP asked to bring policy for affordable drug pricing

THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Ramaiah emphasises need for bone health and osteoporosis diagnosis

RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Nathealth calls for action in 2026-27 Union Budget

NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Hotspots & growth opportunities in biomanufacturing

THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.

time to read

3 mins

November 27, 2025

Chronicle Pharmabiz

Omega Hospitals acquires Cytecare Hospitals

Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Devices sector hails withdrawal of QCOs

THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

'There is urgent need for tech-focused regulatory approach for med devices'

THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.

time to read

2 mins

November 27, 2025

Listen

Translate

Share

-
+

Change font size